March 16, 2017 / 11:36 AM / 8 months ago

BRIEF-PTC Therapeutics to buy Emflaza

March 16 (Reuters) - PTC Therapeutics Inc:

* PTC Therapeutics announces agreement to acquire Emflaza™ for the treatment of duchenne muscular dystrophy in U.S.

* PTC Therapeutics Inc- transaction is expected to be accretive to both earnings and cash flow beginning in 2018

* PTC Therapeutics Inc - deal comprised of approximately $75 million in cash and approximately $65 million in PTC common stock

* PTC Therapeutics Inc- in addition, marathon has opportunity to receive a single $50 million sales-based milestone

* PTC Therapeutics Inc - deal for $140 million upfront consideration

* PTC Therapeutics Inc - Marathon is also entitled to receive payments from ptc based on annual net sales of emflaza beginning in 2018

* PTC Therapeutics Inc- has entered into an asset purchase agreement with Marathon Pharmaceuticals, Llc to acquire all rights to emflaza Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below